DAGLB

Across TCGA pan-cancer cohorts, DAGLB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DAGLB data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DAGLB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DAGLB expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where DAGLB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.672	0.843	.006	21	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	14	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	6	view →
CCRCC	DFS	Median	III,IV	0.585	0.832	.023	2	view →
LSCC	DFS	Median	All	0.907	0.464	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DAGLB–PDAC (DFS)

Open the PDAC breakdown →